Shanghai Pharmaceutical (usa) Inc. - Net Worth and Insider Trading
Shanghai Pharmaceutical (usa) Inc. Net Worth
The estimated net worth of Shanghai Pharmaceutical (usa) Inc. is at least $225,072 dollars as of 2024-11-10. Shanghai Pharmaceutical (usa) Inc. is the 10% Owner of Oncternal Therapeutics Inc and owns about 177,222 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $225,072. Details can be seen in Shanghai Pharmaceutical (usa) Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Shanghai Pharmaceutical (usa) Inc. has not made any transactions after 2020-07-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Shanghai Pharmaceutical (usa) Inc.
Shanghai Pharmaceutical (usa) Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Shanghai Pharmaceutical (usa) Inc. owns 1 companies in total, including Oncternal Therapeutics Inc (ONCT) .
Insider Ownership Summary of Shanghai Pharmaceutical (usa) Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ONCT | Oncternal Therapeutics Inc | 2020-07-21 | 10 percent owner |
Shanghai Pharmaceutical (usa) Inc. Latest Holdings Summary
Shanghai Pharmaceutical (usa) Inc. currently owns a total of 1 stock. Shanghai Pharmaceutical (usa) Inc. owns 177,222 shares of Oncternal Therapeutics Inc (ONCT) as of July 21, 2020, with a value of $225,072.
Latest Holdings of Shanghai Pharmaceutical (usa) Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ONCT | Oncternal Therapeutics Inc | 2020-07-21 | 177,222 | 1.27 | 225,072 |
Holding Weightings of Shanghai Pharmaceutical (usa) Inc.
Shanghai Pharmaceutical (usa) Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Shanghai Pharmaceutical (usa) Inc. has made a total of 1 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 52,466 shares on July 21, 2020, which cost Shanghai Pharmaceutical (usa) Inc. around $2 Million.
Insider Trading History of Shanghai Pharmaceutical (usa) Inc.
- 1
Shanghai Pharmaceutical (usa) Inc. Trading Performance
GuruFocus tracks the stock performance after each of Shanghai Pharmaceutical (usa) Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Shanghai Pharmaceutical (usa) Inc. is -34.25%. GuruFocus also compares Shanghai Pharmaceutical (usa) Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Shanghai Pharmaceutical (usa) Inc. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Shanghai Pharmaceutical (usa) Inc.'s insider trading performs compared to the benchmark.
Performance of Shanghai Pharmaceutical (usa) Inc.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 5.91 | | | | | |
| Relative Return to S&P 500(%) | 1.62 | | | | | |
Shanghai Pharmaceutical (usa) Inc. Ownership Network
Ownership Network List of Shanghai Pharmaceutical (usa) Inc.
Ownership Network Relation of Shanghai Pharmaceutical (usa) Inc.
Shanghai Pharmaceutical (usa) Inc. Owned Company Details
What does Oncternal Therapeutics Inc do?
Who are the key executives at Oncternal Therapeutics Inc?
Shanghai Pharmaceutical (usa) Inc. is the 10 percent owner of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .
Oncternal Therapeutics Inc (ONCT) Insider Trades Summary
Over the past 18 months, Shanghai Pharmaceutical (usa) Inc. made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 28,000 shares made by Gunnar F. Kaufmann , and a net purchase of 980 shares made by David F Hale .
In summary, during the past 3 months, insiders sold 0 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 12,380 shares were bought by its insiders, resulting in a net purchase of 11,400 shares.
Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncternal Therapeutics Inc Insider Transactions
Shanghai Pharmaceutical (usa) Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Shanghai Pharmaceutical (usa) Inc.. You might contact Shanghai Pharmaceutical (usa) Inc. via mailing address: C/o Oncternal Therapeutics, Inc., 3525 Del Mar Heights Road #821, San Diego Ca 92130-2122.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
